



BioGeneration Announces Closing of BioGeneration Ventures II

Naarden, The Netherlands

Tuesday, 10 May 2011

BioGeneration Ventures, a leading Dutch venture capital provider, today announced the first closing of its second life sciences venture capital fund. The new fund called BioGeneration Ventures II is set to continue the successful strategy of the first fund and has a target size of 30 M euro. BioGeneration will continue to invest in young and innovative companies with high growth potential.

BioGeneration Ventures II is currently backed by existing investors in the previous fund and is open for additional new investors. The Dutch Ministry of Economic Affairs, Agriculture and Innovation is also supporting the fund through a TechnoPartner Seed-facility loan.

"We are very pleased with the continued support of our existing investors and the backing of TechnoPartner and are looking forward to continue building a portfolio of successful healthcare and biotech companies the coming years" said Edward van Wezel, the fund's Managing Partner.

Since 2007 BioGeneration Ventures has made investments in 11 companies in the Netherlands and has realized exits in 2 of these opportunities. Current investments include Mucosis BV that recently announced the start of its first human clinical trial for a novel flu vaccine and antibody platform company arGENx BV.

Contact:

Edward van Wezel T: +31 35 699 3000

E: info@biogenerationventures.com

W: <http://www.biogenerationventures.com>

About BioGeneration Ventures

BioGeneration Ventures is a life sciences fund with a focus on novel (academic) technology investments in the Netherlands. The team of BioGeneration consists of investment professionals that are specialized in the evaluation of new technologies and in the management of start-up companies. Since 2007 BioGeneration Ventures has built a portfolio of 11 innovative Life Sciences companies. BioGeneration Ventures was co-founded by the Netherlands Genomics Initiative (NGI), the holding of the University of Leiden, and ABN-AMRO Capital. BioGeneration closely cooperates with Forbion Capital Partners (www.biogenerationventures.com).